XML 24 R13.htm IDEA: XBRL DOCUMENT
v3.22.1

Earnings Per Share | 3 Months Ended
--- | ---
Mar. 31, 2022
Earnings Per Share [Abstract] |
Earnings Per Share |
4. | Earnings Per Share
The following table sets forth the computation of basic and diluted earnings per share for the three months ended March 31, 2022 and 2021 (in thousands, except per share amounts):
|  | Three Months Ended March 31, |
|  | 2022 |  |  | 2021 |
Numerator: |  |  |  |  |  |  |  |
Income from continuing operations attributable to Acadia Healthcare Company, Inc. |  | $ | 60,837 |  |  | $ | 22,358 |
Loss from discontinued operations |  |  | — |  |  |  | (12,641 | )
Net income attributable to Acadia Healthcare Company, Inc. |  | $ | 60,837 |  |  | $ | 9,717 |
Denominator: |  |  |  |  |  |  |  |
Weighted average shares outstanding for basic earnings per share |  |  | 89,258 |  |  |  | 88,242 |
Effects of dilutive instruments |  |  | 1,754 |  |  |  | 1,699 |
Shares used in computing diluted earnings per common share |  |  | 91,012 |  |  |  | 89,941 |
Basic earnings per share attributable to Acadia Healthcare Company, Inc. stockholders: |  |  |  |  |  |  |  |
Income from continuing operations attributable to Acadia Healthcare Company, Inc. |  | $ | 0.68 |  |  | $ | 0.25 |
Loss from discontinued operations |  |  | — |  |  |  | (0.14 | )
Net income attributable to Acadia Healthcare Company, Inc. |  | $ | 0.68 |  |  | $ | 0.11 |
Diluted earnings per share attributable to Acadia Healthcare Company, Inc. stockholders: |  |  |  |  |  |  |  |
Income from continuing operations attributable to Acadia Healthcare Company, Inc. |  | $ | 0.67 |  |  | $ | 0.25 |
Loss from discontinued operations |  |  | — |  |  |  | (0.14 | )
Net income attributable to Acadia Healthcare Company, Inc. |  | $ | 0.67 |  |  | $ | 0.11 |
Approximately 0.7 million shares of common stock issuable upon exercise of outstanding stock option awards were excluded from the calculation of diluted earnings per share for both the three months ended March 31, 2022 and 2021, because their effect would have been anti-dilutive.

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -URI http://asc.fasb.org/topic&trid=2144383 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration